ClinicalTrials.gg
TerminatedNCT01655823TTX-CINP-201Updated Oct 30, 2018Results posted

The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment

A Phase 2 interventional study of Placebo and Tetrodotoxin in Pain, Peripheral Neuropathy and Neuropathic Pain, sponsored by Wex Pharmaceuticals Inc.. Terminated at 23 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-30.

Primary conditionNeuralgiaRegistry: PainReclassifiedWhy we changed it
Registry
Pain — the first condition term the registry derived for this study.
ClinicalTrials.gg
Neuralgia
Why
  1. The study's listed conditions name Neuralgia, a narrower term within Pain.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Wex Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
Interim analysis completed and decided to terminate and proceed to Phase 3 trial.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 291 studies in Neuralgia with a site in United States — 50 open to participants now, 61 under way, 5 of them phase 3. Neuralgia · United States.

Enrollment
58th of 261
125 · median 40
Started
2012
with 16 others
Phase 2
78 of 291
5 open now
Registered
83rd of 291
by date

Among the 291 studies in Neuralgia with a site in United States, this one is the 58th largest by enrollment of the 261 interventional ones that give a count, is one of 17 that started in 2012, is one of 78 in phase 2, and was the 83rd registered.

Neuralgia

1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.

Browse Neuralgia studies →

Open to participants now

50 of the 291 studies in Neuralgia with a site in United States are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 153 Neuralgia studies recruiting now, 77 (50%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 291 studies in Neuralgia with a site in United States, or all of them as a file.
02

Study summary

Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting side effect of many chemotherapeutic agents including vincristine, paclitaxel, cisplatin, oxaliplatin, bortezomib and ixabepilone. Chemotherapy-induced peripheral neuropathy commonly occurs in greater than 40% of patients. To improve the peripheral neuropathy, the chemotherapy dosing is often either decreased or discontinued potentially affecting tumor responsiveness, prognosis, and survival.

There is an unmet medical need for treatment of cancer patients with chemotherapy induced neuropathic pain (CINP) and the proposed study will investigate the efficacy and safety of multiple dose levels of tetrodotoxin (TTX) versus placebo in moderate to severe neuropathic pain caused by chemotherapy.

03

Conditions studied

  • Pain
  • Peripheral Neuropathy
  • Neuropathic Pain

Browse trials for

Keywords

  • Pain
  • Puffer fish
  • Tetrodotoxin
  • TTX
  • Neuropathy
  • Chemotherapy
  • WEX Pharmaceuticals
04

In context

Neuralgia Reclassified

1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.

This study's enrollment of 125 is above the median of 52 across 831 interventional studies indexed under Neuralgia.

Browse Neuralgia studies →

Lead sponsor

Wex Pharmaceuticals Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.

Compared within Neuralgia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pain. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • If female, not of .
  • Patients with documented neuropathic pain
  • Cancer Patients who have completed a chemotherapy regimen which included taxanes or platinums (or both) and have no evidence actively progressive disease. Concurrent hormonal therapies are allowed
  • Patients with stable moderate to severe neuropathic pain
  • Patients with an (ECOG) Performance Status score of 0 or 1.
  • Patients who are able to complete the study-related questionnaires independently in either English or Spanish.

Exclusion criteria

Exclusion Criteria:

  • History of peripheral neuropathy attributed to any cause other than chemotherapy.
  • Patients receiving any concurrent agents known to cause peripheral neuropathy within 30 days of Randomization.
  • Current use of other therapy (ies), including "alternative" therapies, for treatment of peripheral neuropathy within 30 days of Randomization (with the exception of protocol allowed concurrent medications).
  • Patients who used controlled release opioids within seven days of baseline period or who expect to use controlled release opioids at any time from baseline to end of study.
  • Patients with abnormal kidney function.
  • Patients with bone .
  • Patients scheduled for treatment for their cancer with chemotherapy or radiotherapy between screening and the end of study visit.
  • Current use of lidocaine and other types of antiarrhythmic drugs within 30 days of Randomization.
  • Current use of scopolamine and acetylcholinesterase-inhibiting drugs such as physostigmine within 30 days of Randomization.
  • Current cause of Chemotherapy Induced Neuropathic Pain attributed to Velcade (Bortezomib) or vinca alkaloids or analogues such as vincristine, vinblasine, vinorelbine and vindesine.
  • Current use of tricyclic antidepressant medication, anticonvulsants and monoamine oxidase inhibitors.
  • Patients with current uncontrolled asthma or lung disease.
  • Patients with significant heart disease.
  • Use of an agent within 30 days prior to screening or is scheduled to receive an investigational drug other than TTX during the course of the study.
  • Females who are pregnant or nursing
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
125 participants (actual)

Study arms

  • Placebo comparator
    Placebo (twice daily)

    Placebo for injection (1 ml volume), twice a day for four consecutive days.

    Drug: Placebo

  • Experimental
    Low dose Tetrodotoxin (twice daily)

    Low dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.

    Drug: Tetrodotoxin

  • Experimental
    Mid-range dose of Tetrodotoxin (twice daily)

    Mid-range dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.

    Drug: Tetrodotoxin

  • Experimental
    Max dose Tetrodotoxin (once daily)

    Max dose Tetrodotoxin injectable (1 ml volume), once a day in the morning for four consecutive days and Placebo for injection (1 ml volume), once a day in the afternoon for four consecutive days. Total of 4 treatment days.

    Drug: Placebo · Drug: Tetrodotoxin

  • Experimental
    Max dose Tetrodotoxin (twice daily)

    Max dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.

    Drug: Tetrodotoxin

Interventions

  • DrugPlacebo

    Sham treatment acting as control arm

    Also known as: placebo for injection

  • Comparison of different dosages of Tetrodotoxin

    Also known as: TTX for injection

07

What researchers measure

Primary outcomes

  1. Change From Baseline in Patient Reported Outcome for Pain at Day 22 to Day 28.

    The primary efficacy endpoint for Part I was the change from baseline in weekly average NPRS scores at 22 to 28 days after treatment. Baseline was defined as the average of NPRS scores for the last 7 days prior to dosing. Pain was assessed using a Numerical Pain Rating Scale (NPRS) with a range of 0 (no pain) to 10 (extreme pain).

    Time frame: Day 22 to Day 28

08

Results

Posted Oct 30, 2018

Participant flow

Participant flow — Overall Study
MilestonePlacebo (Twice Daily)Low Dose Tetrodotoxin (Twice Daily)Mid-range Dose of Tetrodotoxin (Twice Daily)Max Dose Tetrodotoxin (Once Daily)Max Dose Tetrodotoxin (Twice Daily)
Started2525242526
Completed2523242425
Not completed02011
Withdrew: Lost to follow-up01001
Withdrew: Withdrawal by subject01010

Outcome measures

PrimaryChange From Baseline in Patient Reported Outcome for Pain at Day 22 to Day 28.

The primary efficacy endpoint for Part I was the change from baseline in weekly average NPRS scores at 22 to 28 days after treatment. Baseline was defined as the average of NPRS scores for the last 7 days prior to dosing. Pain was assessed using a Numerical Pain Rating Scale (NPRS) with a range of 0 (no pain) to 10 (extreme pain).

Time frame:
Day 22 to Day 28
Reported as:
Mean · 11 point units on a scale
Change From Baseline in Patient Reported Outcome for Pain at Day 22 to Day 28.
11 point units on a scalePlacebo (Twice Daily)Low Dose Tetrodotoxin (Twice Daily)Mid-range Dose of Tetrodotoxin (Twice Daily)Max Dose Tetrodotoxin (Once Daily)Max Dose Tetrodotoxin (Twice Daily)
Baseline6.662 ± 1.48326.285 ± 1.33127.012 ± 1.37066.240 ± 1.17436.255 ± 1.3561
Mean Scores for Days 22-285.323 ± 2.27655.005 ± 2.04515.987 ± 2.25314.566 ± 2.49314.749 ± 1.7701
Change from Baseline in Mean Scores for Days 22-28-1.339 ± 2.0681-1.269 ± 1.3959-1.052 ± 1.5742-1.682 ± 2.3231-1.529 ± 1.8203

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Twice Daily)—1/25 (4%)18/25 (72%)
Low Dose Tetrodotoxin (Twice Daily)—0/25 (0%)21/25 (84%)
Mid-range Dose of Tetrodotoxin (Twice Daily)—1/24 (4.2%)22/24 (91.7%)
Max Dose Tetrodotoxin (Once Daily)—0/25 (0%)20/25 (80%)
Max Dose Tetrodotoxin (Twice Daily)—1/26 (3.8%)24/26 (92.3%)
Most frequent serious events
Most frequent serious events
EventPlacebo (Twice Daily)Low Dose Tetrodotoxin (Twice Daily)Mid-range Dose of Tetrodotoxin (Twice Daily)Max Dose Tetrodotoxin (Once Daily)Max Dose Tetrodotoxin (Twice Daily)
Metastatic carcinoma of bladder and Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/250/251/240/250/26
Colon cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/250/250/240/250/26
Viral upper respiratory tract infectionInfections and infestations0/250/250/240/251/26
Most frequent other events
Most frequent other events
EventPlacebo (Twice Daily)Low Dose Tetrodotoxin (Twice Daily)Mid-range Dose of Tetrodotoxin (Twice Daily)Max Dose Tetrodotoxin (Once Daily)Max Dose Tetrodotoxin (Twice Daily)
Paraesthesia OralNervous system disorders3/254/259/2410/2511/26
ParaesthesiaNervous system disorders6/255/257/245/2510/26
Hypoaesthesia OralNervous system disorders3/255/257/246/2510/26
headacheNervous system disorders5/256/253/241/259/26
dizzinessNervous system disorders5/253/254/243/258/26
HypoaesthesiaNervous system disorders2/252/251/242/251/26

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo (Twice Daily)Low Dose Tetrodotoxin (Twice Daily)Mid-range Dose of Tetrodotoxin (Twice Daily)Max Dose Tetrodotoxin (Once Daily)Max Dose Tetrodotoxin (Twice Daily)Total
Mean59.0 ± 10.359.1 ± 10.2961.4 ± 10.0160.4 ± 10.2860.6 ± 11.0560.1 ± 10.28
Sex: Female, Male
Sex: Female, Male(Participants)Placebo (Twice Daily)Low Dose Tetrodotoxin (Twice Daily)Mid-range Dose of Tetrodotoxin (Twice Daily)Max Dose Tetrodotoxin (Once Daily)Max Dose Tetrodotoxin (Twice Daily)Total
Female151615151677
Male1099101048
Region of Enrollment
Region of Enrollment(participants)Placebo (Twice Daily)Low Dose Tetrodotoxin (Twice Daily)Mid-range Dose of Tetrodotoxin (Twice Daily)Max Dose Tetrodotoxin (Once Daily)Max Dose Tetrodotoxin (Twice Daily)Total
United States2525242526125
09

Study locations

23 sites
  • Lalita Pandit
    Fountain Valley, California 92708, United States
  • Robert Moss
    Fountain Valley, California 92708, United States
  • Alliance Research Centers
    Laguna Hills, California 92653, United States
  • Global Research Management
    Los Angeles, California 90027, United States
  • Innovative Clinical Research
    Los Angeles, California 90603, United States
  • El Camino Cancer Center
    Mountain View, California 94040, United States
  • Pacific Cancer Care
    Salinas, California 93901, United States
  • Redwood Regional Medical Group
    Santa Rosa, California 95403, United States
  • St. Vincent's Medical Center
    Bridgeport, Connecticut 06606, United States
  • Medsol Clinical Research Center
    Port Charlotte, Florida 33952, United States
  • Axcess Medical Research
    Wellington, Florida 33414, United States
  • Cancer Center of Middle Georgia
    Dublin, Georgia 31021, United States
  • Cancer Center of Kansas
    Wichita, Kansas 67214, United States
  • Center for Cancer and Blood Disorders
    Bethesda, Maryland 20817, United States
  • St. Louis Cancer Care
    Bridgeton, Missouri 63044, United States
  • Mercy Medical Research Institute
    Springfield, Missouri 65807, United States
  • John Theurer Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • New Mexico Oncology Hematology Consultants
    Albuquerque, New Mexico 87103, United States
  • Signal Point Clinical Research Center
    Middletown, Ohio 45042, United States
  • Institute of Pain Research
    Oklahoma City, Oklahoma 73104, United States
  • Gettysburg Cancer Center
    Gettysburg, Pennsylvania 17325, United States
  • University of Texas Southwestern
    Dallas, Texas 75390-9179, United States
  • Jean Brown Research
    Salt Lake City, Utah 84124, United States
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Jan 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2018, 3 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2012
First posted
Aug 2, 2012
Start
Jul 2012
Primary completionActual
Jan 2015
CompletionActual
Feb 11, 2015
Results first posted
Oct 30, 2018
Last update
Oct 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01655823
Lead sponsor
Wex Pharmaceuticals Inc.
Collaborators
Premier Research Group plc
Responsible party
Sponsor
First posted
Aug 2, 2012
Start date
Jul 2012
Primary completion
Jan 2015
Completion
Feb 11, 2015
Results posted
Oct 30, 2018
Last update
Oct 30, 2018

Study contacts

Samuel Goldlust, MD
principal investigator · Hackensack University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tetrodotoxin

Start the discussion